Guangzhou Baiyunshan Pharmaceutical Holdings Co (600332.SS) Stock Price
Guangzhou Baiyunshan Pharmaceutical Holdings Co Price
Guangzhou Baiyunshan Pharmaceutical Holdings Co (600332.SS) Stock | ISIN CNE000001733. The current Guangzhou Baiyunshan Pharmaceutical Holdings Co stock price is 21.5 CNY (2026). Revenue is 83.68 B CNY. Net income is 3.55 B CNY. The P/E ratio is 9.86. Market capitalization is 34.95 B CNY. Guangzhou Baiyunshan Pharmaceutical Holdings Co operates in the Health sector.
Guangzhou Baiyunshan Pharmaceutical Holdings Co stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Guangzhou Baiyunshan Pharmaceutical Holdings Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Guangzhou Baiyunshan Pharmaceutical Holdings Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Guangzhou Baiyunshan Pharmaceutical Holdings Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Guangzhou Baiyunshan Pharmaceutical Holdings Co Price |
|---|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Guangzhou Baiyunshan Pharmaceutical Holdings Co Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B CNY) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (B CNY) |
| NET INCOME (B CNY) |
| NET INCOME GROWTH (%) |
| DIVIDEND (CNY)DIV. (CNY) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (B) |
| DOCUMENTS |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|
| 61.67 | 69.01 | 70.79 | 75.52 | 74.99 | 79.39 | 83.68 | 90.35 |
| -5.05 | 11.9 | 2.57 | 6.68 | -0.69 | 5.86 | 5.4 | 7.97 |
| 16.89 | 19.16 | 18.75 | 18.78 | 16.67 | 15.74 | 14.94 | 13.83 |
| 10.42 | 13.22 | 13.27 | 14.18 | 12.5 | 12.5 | 12.5 | 12.5 |
| 2.92 | 3.72 | 3.97 | 4.06 | 2.84 | 3.3 | 3.55 | 4.47 |
| -8.59 | 27.58 | 6.64 | 2.24 | -30.09 | 16.4 | 7.45 | 25.94 |
| 0.59 | 0.54 | 0.69 | 0.73 | 1.15 | 0.8 | 0.6 | 0.75 |
| 40.48 | -8.47 | 27.78 | 5.8 | 57.53 | -30.43 | -25 | 25 |
| 1.63 | 1.63 | 1.63 | 1.63 | 1.63 | 1.63 | 1.63 | 1.63 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Guangzhou Baiyunshan Pharmaceutical Holdings Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Guangzhou Baiyunshan Pharmaceutical Holdings Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Guangzhou Baiyunshan Pharmaceutical Holdings Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Guangzhou Baiyunshan Pharmaceutical Holdings Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Guangzhou Baiyunshan Pharmaceutical Holdings Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Guangzhou Baiyunshan Pharmaceutical Holdings Co stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Guangzhou Baiyunshan Pharmaceutical Holdings Co Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Guangzhou Baiyunshan Pharmaceutical Holdings Co business model & stock analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Co SWOT Analysis
Strengths
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (Baiyunshan) holds several key strengths that contribute to its success in the pharmaceutical industry.
1. Established Brand: Baiyunshan has built a strong brand image and is recognized as one of the leading pharmaceutical companies in China. Its brand reputation and trust among consumers give it a competitive edge in the market.
2. Diverse Product Portfolio: The company offers a wide range of pharmaceutical products, including medicines, health supplements, and traditional Chinese medicines. This diversification provides a stable revenue stream and reduces dependence on any single product category.
3. Research and Development (R&D) Capabilities: Baiyunshan invests significantly in R&D, enabling it to develop innovative products and stay ahead of competitors. Its strong R&D capabilities enhance product quality and allow for the introduction of new drugs.
4. Established Distribution Network: Baiyunshan has an extensive distribution network across China, including partnerships with hospitals, pharmacies, and online platforms. This wide reach ensures efficient product distribution and market penetration.
Weaknesses
Despite its strengths, Baiyunshan also faces several weaknesses that may pose challenges to its growth and competitiveness.
1. Heavy Reliance on Domestic Market: The company primarily operates within China, making it vulnerable to fluctuations in the domestic market. Expanding into international markets could help mitigate this risk.
2. Limited Global Presence: Baiyunshan has limited brand recognition and market presence outside of China. This limits its potential for international expansion and partnerships with global pharmaceutical companies.
3. Regulatory Challenges: The pharmaceutical industry is subject to stringent regulations and quality control measures. Compliance with these regulations can be time-consuming and costly, impacting the company's profitability.
Opportunities
Baiyunshan can leverage several opportunities to further strengthen its position in the market.
1. Growing Chinese Pharmaceutical Market: The Chinese pharmaceutical market continues to expand rapidly with increasing healthcare expenditure and a larger aging population. Baiyunshan can tap into this market growth by introducing new products and targeting specific healthcare needs.
2. International Expansion: Exploring opportunities for expansion into international markets can diversify the company's revenue streams and reduce dependence on the domestic market. This may involve collaborations, partnerships, or acquisitions with global pharmaceutical players.
3. Embracing Digital Transformation: The rise of digital technologies presents opportunities to streamline operations, improve supply chain efficiency, and enhance customer experience. Baiyunshan should invest in digital solutions to stay competitive and cater to evolving consumer demands.
Threats
Baiyunshan faces certain threats that could impact its growth and profitability.
1. Intense Competition: The pharmaceutical industry is highly competitive, with numerous local and international players vying for market share. Baiyunshan must continuously innovate and develop differentiated products to stay ahead of the competition.
2. Patent Expirations: The expiration of patents on key products can lead to increased competition from generic drug manufacturers. Baiyunshan needs to invest in R&D to create new products and maintain a competitive edge.
3. Pricing Pressure: Pricing pressures and government regulations can impact the profitability of pharmaceutical companies. Baiyunshan should monitor pricing trends and optimize its cost structures to remain profitable.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Eulerpool Fair Value
Guangzhou Baiyunshan Pharmaceutical Holdings Co historical P/E ratio, EBIT multiple, and P/S ratio
Guangzhou Baiyunshan Pharmaceutical Holdings Co annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Guangzhou Baiyunshan Pharmaceutical Holdings Co shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Guangzhou Baiyunshan Pharmaceutical Holdings Co Dividend History
23 years of dividend payments
Guangzhou Baiyunshan Pharmaceutical Holdings Co dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Guangzhou Baiyunshan Pharmaceutical Holdings Co dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Guangzhou Baiyunshan Pharmaceutical Holdings Co Earnings Estimates
Guangzhou Baiyunshan Pharmaceutical Holdings Co Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 10/25/2022 | 0.41CNY | -CNY | 2022 Q3 |
| 8/19/2022 | 0.37CNY | -CNY | 2022 Q2 |
| 4/26/2022 | 0.66CNY | -CNY | 2022 Q1 |
| 3/18/2022 | 0.24CNY | -CNY | 2021 Q4 |
| 10/26/2021 | 0.38CNY | -CNY | 2021 Q3 |
| 8/18/2021 | 0.39CNY | -CNY | 2021 Q2 |
| 4/28/2021 | 0.57CNY | -CNY | 2021 Q1 |
| 3/18/2021 | 0.27CNY | -CNY | 2020 Q4 |
| 10/28/2020 | 0.42CNY | -CNY | 2020 Q3 |
| 8/25/2020 | 0.49CNY | -CNY | 2020 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Guangzhou Baiyunshan Pharmaceutical Holdings Co stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Guangzhou Baiyunshan Pharmaceutical Holdings Co shareholder structure
| % | Name |
|---|---|
45.043% | |
4.15651% | |
2.908% | |
1.05113% | |
0.76573% | |
0.7109% | |
0.54098% | |
0.53393% | |
0.48411% | |
0.27518% |
Guangzhou Baiyunshan Pharmaceutical Holdings Co Executives and Management Board
Mr. Jun Yang
(56)Executive Vice Chairman of the Board · since 2020
Ms. Ning Cheng
(59)Executive Vice Chairman of the Board · since 2012
Mr. Jianxiong Zheng
(55)Deputy General Manager
Mr. Hong Li
(58)General Manager, Executive Director · since 2017
Ms. Haoshan Zheng
(49)Deputy General Manager
Guangzhou Baiyunshan Pharmaceutical Holdings Co Supply Chain
Frequently asked questions about Guangzhou Baiyunshan Pharmaceutical Holdings Co
The main competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd in the market include Shanghai Pharmaceuticals Holding Co Ltd, Jiangsu Hengrui Medicine Co Ltd, and Tasly Pharmaceutical Group Co Ltd.
Guangzhou Baiyunshan Pharmaceutical Holdings Co stock
Guangzhou Baiyunshan Pharmaceutical Holdings Co Peer Group
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ticker
Guangzhou Baiyunshan Pharmaceutical Holdings Co FIGI
All fundamentals and in-depth analysis of Guangzhou Baiyunshan Pharmaceutical Holdings Co
Our stock analysis for Guangzhou Baiyunshan Pharmaceutical Holdings Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Guangzhou Baiyunshan Pharmaceutical Holdings Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.